Marcus evans...

44
Funding & Commercialization Strategies for Regenerative Medicine Companies Gregory A. Bonfiglio Proteus Venture Partners November 15, 2011

description

Overview of the commercial translation of cell therapies and regenerative medicine by Greg Bonfiglio, Proteus Venture Partners

Transcript of Marcus evans...

Page 1: Marcus evans 2011_commercial_translation_of_regenerative_medicine__funding_strategies_for_rm_companies

Funding & Commercialization Strategies for Regenerative Medicine Companies

Gregory A. BonfiglioProteus Venture Partners"November 15, 2011"

Page 2: Marcus evans 2011_commercial_translation_of_regenerative_medicine__funding_strategies_for_rm_companies

Agenda

I.  The RM Market Is Entering A New Era §  RM Has Made Great Progress §  But Serious Commercialization Challenges Remain

II.  New Economic Realties §  A Fundamental Shift in Biotech Economics §  The Valley of Death Is Expanding §  A New Capital Efficient Model Is Required

II.  The Role of RM Translation Centers §  Enabling Capital Efficient RM Technology Development §  Facilitating Collaborations in RM Technology Development §  The RMC: An International Coalition of RMTCs

CONFIDENTIAL 2

Page 3: Marcus evans 2011_commercial_translation_of_regenerative_medicine__funding_strategies_for_rm_companies

Gartner’s Hype Cycle of Emerging Technologies

CONFIDENTIAL 3

Technology Trigger

Peak of Inflated Expectations

Trough of Disillusionment

Slope of Enlightment

Plateau of Productivity Time"

Visibility"

Page 4: Marcus evans 2011_commercial_translation_of_regenerative_medicine__funding_strategies_for_rm_companies

RM Market: On 2nd Half of the Gartner Curve

Stage of Development"

Visibility"

Technology Trigger"

Peak of Inflated Expectations"

Trough of Disillusionment"

Slope of Enlightment"

Plateau of Productivity"

1980 Early TE research (MIT)"

1986 ATS and Organogenesis founded"

1988 SyStemix founded"

1992 Geron founded"

1997 First FDA approved cell therapy (Carticel)"

1997 Dolly the sheep"

1998 Human ESCs first derived"

1999 First FDA approved TE product (Apligraf)"

1999 TE bladders in clinic"

2000 Time Magazine:TE No. 1 job"

2001 Bush “partial ban” on HESCs"

2001 Dermagraft FDA approved"

2001 Ortec FDA approved"

2001: 3300 jobs, 73 firms, mkt cap > $2.5B"

2002 ISSCR Founded"

2002 ATS + Organogenesis file" Chapter 11"

Time"

2009 Obama Ends Ban on hESCs"

2007 iPS Technology Developed "

2005 CIRM Founded"

2003 UK Stem Cell Bank Formed"

CONFIDENTIAL 4

2010 Dendreon’s Provenge Approved"

2010 Cephalon & Mesoblast $2B Deal"

Nov 2008 Genzyme-Osiris $1.25B Deal"

2011 Shire Acquires ABH -$750M "

2007 Apligraf - 200,000 Patients Treated"2006 Carticel - 10,000 Patients Treated"

Page 5: Marcus evans 2011_commercial_translation_of_regenerative_medicine__funding_strategies_for_rm_companies

RM Is Entering A New ERA

RM Market is Maturing: Key Metrics

Rapidly Expanding Market: •  $1.6B in 2010 •  $20.0B in 2025 •  CAGR of 18.34%

Dramatic Revenue Growth •  $130M in 2001 •  $1.6B+ in 2010

Worldwide funding for research Increasing •  $2.5B Now •  $14B in 10 Years

Clinical Programs •  Over 3600 Clinical Trials •  Over 400 ex-Oncology

Commercial Products •  400 on Market (Mostly Skin, Tools

Media, & Devices); –  900+ in Development

•  44 Cell Therapies on Market –  $1B Revenues –  400 in Development –  28 in PIII/Pivotal Trials

1.2M+ Patients Treated with RM Products.

•  320K+ Cell Therapy Patients

RM Companies •  600+ Co’s involved in RM •  50+ Public Co’s;

–  $8.7B Total Market Cap •  225+ Private Co’s

CONFIDENTIAL 5

Page 6: Marcus evans 2011_commercial_translation_of_regenerative_medicine__funding_strategies_for_rm_companies

RM Market: Expanding Rapidly

CONFIDENTIAL 6

Cell Therapy Industry: Billion Dollar Global Business With Unlimited Potential; "Regenerative Medicine; Chris Mason, David Brindley, Emily J Culme-Seymour & Natasha L Davie"

Dramatic Cell Therapy Revenue Growth

CTI Revenues: $410M (2008) - $5.1B (2014)"

Page 7: Marcus evans 2011_commercial_translation_of_regenerative_medicine__funding_strategies_for_rm_companies

Global Company Distribution

5%

Asia 32 firms

3%

Canada 24 firms

56%

USA 386 firms

14%

Europe (ex. UK) 93 firms

UK 133 firms

19%

2%

Middle East 17 firms

600+ RM companies worldwide!"

CONFIDENTIAL 7

Page 8: Marcus evans 2011_commercial_translation_of_regenerative_medicine__funding_strategies_for_rm_companies

RM Has Made Great Progress, but… ….Challenges Remain

R&D

§  Creation And Characterization Of Optimal Cells For Therapy –  Controlling Differentiation Pathways

§  Standards For The Field –  What is an iPS Cell? …or MSC?

§  Contaminant Free Cell Lines

§  Safe & Reliable Expansion

§  Track Cell Migration & Engraftment

-  Imaging Technology And Biological Markers

§  Immune Modulation

Manufacturing

§  Technologies For Scale-up -  Safe & Reliable Expansion

-  Sterility Testing & Validation

-  Process Control & Reproducibility; Consistent Lots

-  Closed Systems

§  Product Characterization –  Safety; Identify; Potency

§  Process Control : Process Is The Product –  COGS; QC; & cGMP

§  Centralized Vs. Point Of Care

CONFIDENTIAL 8

Page 9: Marcus evans 2011_commercial_translation_of_regenerative_medicine__funding_strategies_for_rm_companies

…A Few More Challenges

Regulatory& IP Landscape

§  Regulatory Environment Needs Clarity -  Standards & Guidelines Are Evolving

-  Characterization

-  Safety / Efficacy / Consistency

-  Cross Border Inconsistencies

§  IP Landscape Is Treacherous : “Patent Thicket” -  Fragmented Ownership;

-  Patents Proliferating Rapidly : 25% GAGR

-  Inconsistent & Competing Patents: Invites Litigation

-  Need “Freedom To Operate” Opinions

Business Issues

§  Business Model Questions -  Capital Efficient R&D

-  Product V. Service Models

-  Autologous V. Allogeneic

§  Reimbursement Issues -  Cost Savings Justification

§  Sales & Marketing -  Complex Channel Arrangements

-  Define Marketable “Product”

-  Educate Consumers Re: New Treatment Paradigms

CONFIDENTIAL 9

Page 10: Marcus evans 2011_commercial_translation_of_regenerative_medicine__funding_strategies_for_rm_companies

RM Business Models: Autologous v. Allogeneic

Autologous Model

Patients Own Cells/Tissue •  Personalized Medicine

Advantages: •  Easier Regulatory Path

(GTP) •  No Immune Response

Challenges: •  Difficult to Scale •  High COGS

Allogeneic Model

Universal Cells in a Bottle •  Big Pharma “Drug Model”

Advantages: •  Scalable •  Low COGS

Challenges: •  More Difficult Regulatory

Path •  Immune Response

CONFIDENTIAL 10

Service vs. Product"

•  Autologous Treatment for Prostate Cancer Using Dendritic Cells -Centralized Processing

•  $93K per Treatment -$1B+ Projected Revenues

•  $5.0B Market Cap (Until Aug 3, 2011)

Page 11: Marcus evans 2011_commercial_translation_of_regenerative_medicine__funding_strategies_for_rm_companies

Agenda

I.  The RM Market Is Entering A New Era §  RM Has Made Great Progress §  But Serious Commercialization Challenges Remain

II.  New Economic Realties §  A Fundamental Shift in Biotech Economics §  The Valley of Death Is Expanding §  A New Capital Efficient Model Is Required

II.  The Role of RM Translation Centers §  Enabling Capital Efficient RM Technology Development §  Facilitating Collaborations in RM Technology Development §  The RMC: An International Coalition of RMTCs

CONFIDENTIAL 11

Page 12: Marcus evans 2011_commercial_translation_of_regenerative_medicine__funding_strategies_for_rm_companies

New Economic Reality"

Coming Out (?) of the Worst Financial Crisis in 75+ Years

CONFIDENTIAL 12

Page 13: Marcus evans 2011_commercial_translation_of_regenerative_medicine__funding_strategies_for_rm_companies

Dendreon is a Success Story, But….

CONFIDENTIAL 13

…Also a Cautionary Tale August 3, 2011 "

"" Dendreon plunges 67% on slow sales, plans 'across the board'

layoffs""

Dendreon slashed its sales forecast for 2011 Wednesday "after reporting lower than expected second-quarter net revenue of $49.6 million."

August 18, 2011""" Biotech Stocks Battle The ‘Dendreon Effect’" Company’s Troubles With Provenge Chill Fellow Drug Makers" "

Page 14: Marcus evans 2011_commercial_translation_of_regenerative_medicine__funding_strategies_for_rm_companies

Basic & DiscoveryResearch"

Preclinical" Research"

Venture Investments"Grants to Universities & Research Institutes,"

IPO & Partnering Deals"

TherapeuticCandidate"

Product Release"

Proof of Concept."

PI"$10-15MM"

Probability: 66%"

Probability: 70%"

Probability: 40%"

Preclinical" Development"

Clinical" Phase I"

Clinical" Phase II"

Clinical" Phase III" Market"

1-3 years" 1.4-1.8 year" 2.5-3.8 years"

PII"$20-25MM"

PIII"$50-75MM"

IND" Safety" Efficacy"

Biotech Product Development Is "Dependent on External Funding "

Probability"of success"

Steps"

Outcome"

Investment"Amount"

Actors"

$5-10MM" $75=100MM"

CONFIDENTIAL 14

Key Metrics:"

•  Average Time to Market: 10-15 Years"•  Average Costs: $1B"

•  Failure Rate: @90%"•  Less than 30% of approved drugs recoup development costs"

Page 15: Marcus evans 2011_commercial_translation_of_regenerative_medicine__funding_strategies_for_rm_companies

Venture Capital: VCs Want “Pristine Deals”

Proprietary Commercial Technology §  Great Science ≠ Great Business §  Proof Of Concept Established §  Phase II Clinical Data

Strong Management Team §  Board §  SAB

Solid Intellectual Property Position §  Freedom To Operate §  Defensible IP (Patents & Trade

Secrets)

Large Market Opportunity §  Target markets > $1B/year

Defensible Business Model §  Capital Efficient Tech Development §  Application Engines §  Project Based Models §  Virtual Operations

Differentiation §  How Is Your Approach Different? §  Why Is It Better?

Exit Strategy §  M&A: Attractive Products For Acquirer §  Realistic Timeframe

Acceptable Risk/Return Profile §  Multiple Chances To Win

CONFIDENTIAL 15

Page 16: Marcus evans 2011_commercial_translation_of_regenerative_medicine__funding_strategies_for_rm_companies

Public Capital Markets: Financing Alternatives

8

Equity

SEC Registration Required Upfront

Follow-On (Fully Marketed)

Company sells registered shares under an effective shelf registration statement (or a specific registration statement) to public investors after a traditional 2 to 5 day roadshow

At-the-Market (ATM)

Company sells registered shares under an effective shelf registration statement to investors into the general trading market over an extended period of time

Underwritten Registered Direct

(URD)

Company sells registered shares under an effective shelf registration statement to public investors after a 1 to 3 day confidential roadshow

Registered Direct (RD)

Company sells registered securities under an effective shelf registration statement to a targeted group of institutional investors on a confidential basis

No Upfront SEC Registration

Required

Common Stock PIPE

Company sells unregistered shares to a targeted group of institutional investors in a private placement and files to register the securities typically within 30 days after the offering

Convertible Preferred/Debt

Convertible PIPE

Company sells unregistered convertible preferred stock/convertible debt to a targeted group of institutional investors in a private placement and files to register the securities typically within 30 days after the offering

Rule 144A Convertible Debt

Company sells unregistered convertible debt securities to institutional investors in a Rule 144A offering and files to register the securities typically within 90 days after the offering (public style execution)

Public Transactions Private/Quasi-Public Transactions

CONFIDENTIAL 16

Key Strategies: IPO - 2ndary - Shelf Registration - PIPE

[Source: Robin Smith – NeoStem]"

Page 17: Marcus evans 2011_commercial_translation_of_regenerative_medicine__funding_strategies_for_rm_companies

The Old “Relay” Model Is Very Capital Intensive

Business Models: •  “Platform” Company

•  Develop technology horizontally across many therapeutic applications •  High research cash burn •  Large R&D staff

•  “Product” Company (Specialty Pharma) •  Apply technology to specific therapeutic applications •  Multiple clinical programs •  Large clinical trial burn rate

IPO Metrics: •  Lead Program in late stage development •  Additional “shots on goal” (earlier clinical programs, or platform technologies) •  Substantial infrastructure (“bricks & mortar” & staff)

CONFIDENTIAL 17

Strategy: Build Company Toward An IPO

Pre-IPO Capital: @$90M"

Page 18: Marcus evans 2011_commercial_translation_of_regenerative_medicine__funding_strategies_for_rm_companies

The New Economic Reality

Public Markets: Closed? •  Biotech IPO Performance: Very Poor

•  2003-2007 Window: 77 Companies •  Average VC Return = 1.9X •  Oct 2007 (Market Peak): 59% trading below initial PPS •  June 2009: 79% trading below initial PPS •  69% Trading Below Total Invested Capital

•  Only 13 Biotech IPOs in the last 24 months; All Performed Poorly* (Reduced Capital Raised; Reduced Offering Price; Trading Below IPO price)

Private Equity: Dramatically Reduced •  Venture Investments in Biotech are Down 45+%

•  Back to pre=1990s level of capital (PWC Survey)

•  VCs have fled Early Stage investments •  First-Time Financings at Some of the Lowest Levels in 40 Years

CONFIDENTIAL 18

Traditional Capital Sources Are Unavailable

Page 19: Marcus evans 2011_commercial_translation_of_regenerative_medicine__funding_strategies_for_rm_companies

Global Biotech IPOs: 2002 - 2010

CONFIDENTIAL 19

Source: Nature Biotechnology 29, 585–591 (2011)"

Page 20: Marcus evans 2011_commercial_translation_of_regenerative_medicine__funding_strategies_for_rm_companies

GLOBAL BIOTECH FINANCING

CONFIDENTIAL 20

Source: Nature Biotechnology 29, 585–591 (2011)"

Page 21: Marcus evans 2011_commercial_translation_of_regenerative_medicine__funding_strategies_for_rm_companies

Funding Sources: Government Funds

UK & EU Development Funds: MRC; Framework 7; European Research Council

Traditional US Government Funding Increasing §  NIH Funding & DARPA

Non-Traditional US Government Funding Is Available §  DoD RM Initiate: AFIRM (Armed Forces Institute of Regenerative

Medicine) §  HHS Initiative: BARDA (Biomedical Advanced Research and

Development Authority)

State RM Funds: CIRM Actively Funding ($1.2BM); Many Other US States

Other Regional Development Funds: Singapore EDB/Bio*One Fund; UK Matching Grants; Gulf; India §  Tech Transfer; Develop Biotech Industry

CONFIDENTIAL 21

Page 22: Marcus evans 2011_commercial_translation_of_regenerative_medicine__funding_strategies_for_rm_companies

RESEARCH DEVELOPMENT CLINICAL TRIALS (Phase 1 and 2)

2-3 years 2-3 years 3-4 years

Institutional Funding Is Not Readily Available Until Phase 2 Trials

“Valley of Death” Grants & Seed Money

VC Investments Available

The Valley of Death Is Expanding

CONFIDENTIAL 22

Page 23: Marcus evans 2011_commercial_translation_of_regenerative_medicine__funding_strategies_for_rm_companies

“It’s a Very Tough Environment”

25% of All Biotech Companies have Failed since 2007

Delistings & Bankruptcies in 2008 •  22 Public Companies were Delisted from NASDAQ

•  214% increase over 2007 (7 Companies) •  6 Public Companies filed for Bankruptcy

•  200% increase over 2007 ( 2)

Biotech Casualties in 2009: •  44 Public Companies Lost (Delistings; M&A; BKs)

Cash Shortfalls (Oct 2010) •  25% (73) Public Companies have less than 6 months cash

•  Better than Dec 2008: 45% of Public Co’s Had Cash Shortfall

CONFIDENTIAL 23

Many Biotech Companies in Peril

Future Losses: "@5% will Fail in Next 12-18 months "

Page 24: Marcus evans 2011_commercial_translation_of_regenerative_medicine__funding_strategies_for_rm_companies

“It’s a Very Tough Environment”

CONFIDENTIAL 24

" " " " " " November 14, 2011!"

" Geron Halting Stem Cell Research, Laying Off Staff, Stem Cell Pioneer Exits Field "

Geron exiting such research, laying off staff, to focus on cancer drug tests!!

MENLO PARK, Calif. (AP) -- Money troubles have forced the first company doing a government-approved test of embryonic stem cell therapy to discontinue further stem cell programs and lay off much of its staff. "

" " " ">>>>>>>"In a statement, the company said the decision to narrow its focus "was made after a strategic review of the costs, ... timelines and clinical, manufacturing and regulatory complexities associated with the company's research and clinical-stage assets.". "

! "

Page 25: Marcus evans 2011_commercial_translation_of_regenerative_medicine__funding_strategies_for_rm_companies

GERON hESC Program: “POST-MORTUM”

Page 26: Marcus evans 2011_commercial_translation_of_regenerative_medicine__funding_strategies_for_rm_companies

WHAT CAN WE LEARN FROM GERON?

Page 27: Marcus evans 2011_commercial_translation_of_regenerative_medicine__funding_strategies_for_rm_companies

A New Model Is Required: Capital Efficiency Is Critical

CAPITAL EFFICIENCY: DO MORE WITH LESS

Extend Technology Development In Academic Setting •  Thru Phase II

Pursue Alternate Funding Sources •  Government Grants (NIH, DARPA, BARDA; Regional Development Funds;

Foundations & Disease Advocacy Groups; Partner with Pharma/Big Bio

Focus & Conserve Resources •  Focus On Core Business & Projects •  Reduce Infrastructure & Staffing •  Outsource Clinical Development (CRO; RMTs) & Manufacturing (CMO )

Collaborate & Share Resources •  Open Innovation Model •  Share Facilities, Technologies, Staff & IP Resources

CONFIDENTIAL 27

Page 28: Marcus evans 2011_commercial_translation_of_regenerative_medicine__funding_strategies_for_rm_companies

A New Model Is Required: Capital Efficiency Is Critical

CAPITAL EFFICIENT BUSINESS MODELS

Virtual Company •  Outsource Clinical Development To RMTC or CRO •  Outsource Manufacturing To CMO •  Reduce Infrastructure & Staffing

•  Project Based - POC Model •  Fund Specific Projects/Clinical Programs - Focus On Most

Compelling Therapeutic Application •  Create & Fund Company Post-POC Data

•  Partnering Model •  Collaborative R&D •  Shared Facilities, Staff, IP, and Other Resources

CONFIDENTIAL 28

Page 29: Marcus evans 2011_commercial_translation_of_regenerative_medicine__funding_strategies_for_rm_companies

Agenda

I.  The RM Market Is Entering A New Era §  RM Has Made Great Progress §  But Serious Commercialization Challenges Remain

II.  New Economic Realties §  A Fundamental Shift in Biotech Economics §  The Valley of Death Is Expanding §  A New Capital Efficient Model Is Required

II.  The Role of RM Translation Centers §  Enabling Capital Efficient RM Technology Development §  Facilitating Collaborations in RM Technology Development §  The RMC: An International Coalition of RMTCs

CONFIDENTIAL 29

Page 30: Marcus evans 2011_commercial_translation_of_regenerative_medicine__funding_strategies_for_rm_companies

The Role of RM Translation Centers: Enabling Capital Efficient Technology Development

RM Translation Centers Offer

•  State of the Art Facilities -  cGLP & cGMP Compliant -  Focused on Specific RM Technologies

•  Access Deep Domain Knowledge in RM –  Core Expertise in Associated Academic Institution –  History of Collaboration

•  Clinical Development Expertise –  Preclinical Thru Phase II

•  Experienced Support Services –  Incubator/Accelerator

CONFIDENTIAL 30

Page 31: Marcus evans 2011_commercial_translation_of_regenerative_medicine__funding_strategies_for_rm_companies

The Role of RM Translation Centers: Enabling Capital Efficient Technology Development

New RM Venture - Virtual Co

- POC Project - Application Engine

Funding Sources

•  Profit •  Non-Profit •  Government

RM Translation Centers

•  GLP/GMP Facilities •  RM Expertise •  Clinical Development

Experience

Pharma •  Clinical

Development •  Manufacturing •  Marketing •  Reimbursement

CONFIDENTIAL 31

Collaborative Research Leveraging Shared Resources

Open Innovation, Henry Chesbrough , Harvard Business School Press, 2006 "

Page 32: Marcus evans 2011_commercial_translation_of_regenerative_medicine__funding_strategies_for_rm_companies

RM Translation Centers

The Role of RM Translation Centers: Enabling Capital Efficient Technology Development

CONFIDENTIAL 32

Page 33: Marcus evans 2011_commercial_translation_of_regenerative_medicine__funding_strategies_for_rm_companies

RM Translation Centers

The Role of RM Translation Centers: Enabling Capital Efficient Technology Development

CONFIDENTIAL 33

UCI Stem Cell Research Center"

Clinical Cell and Vaccine Production Facility"

USC & UCSF RM Centers "

Page 34: Marcus evans 2011_commercial_translation_of_regenerative_medicine__funding_strategies_for_rm_companies

Regenerative Medicine Coalition: A Coalition of RM Translation Centers

Mission of the RMC

Page 35: Marcus evans 2011_commercial_translation_of_regenerative_medicine__funding_strategies_for_rm_companies

Regenerative Medicine Coalition: A Coalition of RM Translation Centers

RMC

Core Members: RM Translation Centers

Associate Members: -Pharma -Biotech -Emerging RM Companies -Funding Agencies

CONFIDENTIAL 35

Page 36: Marcus evans 2011_commercial_translation_of_regenerative_medicine__funding_strategies_for_rm_companies

Regenerative Medicine Coalition: Charter Members

CONFIDENTIAL 36

Page 37: Marcus evans 2011_commercial_translation_of_regenerative_medicine__funding_strategies_for_rm_companies

Regenerative Medicine Coalition: Finance & Industry Support

CONFIDENTIAL 37

Page 38: Marcus evans 2011_commercial_translation_of_regenerative_medicine__funding_strategies_for_rm_companies

CONFIDENTIAL 38

The Final Word

Page 39: Marcus evans 2011_commercial_translation_of_regenerative_medicine__funding_strategies_for_rm_companies

CONFIDENTIAL 39

APPENDIX

Page 40: Marcus evans 2011_commercial_translation_of_regenerative_medicine__funding_strategies_for_rm_companies

CONFIDENTIAL 40

Proteus: An Investment and Advisory Firm Focused on RM

Proteus, Inc."

Proteus Management, LLC"

"(Fund Management) "

Proteus Insights, LLC"

"(Consulting Services) "

Proteus Advisors, LLC"

"(Investment

Banking Services)"

Page 41: Marcus evans 2011_commercial_translation_of_regenerative_medicine__funding_strategies_for_rm_companies

Funding Sources: Corporate & Non-Profit

Philanthropic Foundations & Disease Advocacy Groups Provide Funding §  JDRF; Michael J. Fox Foundation, CNS Foundation §  Stowers Institute

Corporate Venture Groups

§  JJDC (Tengion; NovoCell) §  Pfizer; NovoNordisk; GE Healthcare; Genzyme

Creative Sources of Funds:

§  Out license non-core technology §  Provide consulting or lab services to generate cash flow §  Work with a strategic partner

§  Biotech, Pharma & Device Companies §  Merge with a cash rich company that is tech poor

CONFIDENTIAL 41

Page 42: Marcus evans 2011_commercial_translation_of_regenerative_medicine__funding_strategies_for_rm_companies

RM IP Landscape: A Patent Thicket

Key Patent Metrics (1980-2005)

Substantial Activity •  Patent Applications: 10,000+ •  Patents Granted: 2,200+

Dramatic Increase in Filings Since 2000

•  Over 25% Annual Growth Rate Geographic Patent Distribution: US Dominates

•  US: Over 50% of Patents •  UK, Canada, Germany: @4% Each •  Australia, Japan, China, Israel: @3%

Each

Top 50 Patents Cover Core Technologies •  Cell Lines; Media; Differentiation

CONFIDENTIAL 42

RM  Patents  Granted  

US:  51%

UK:  4%  

Canada:  4%

Germany:  4%Australia:  3%

Page 43: Marcus evans 2011_commercial_translation_of_regenerative_medicine__funding_strategies_for_rm_companies

RM IP Landscape: A Patent Thicket

Key US RM Patent Metrics

CONFIDENTIAL 43

"§  Unusual Patent Distribution"

-  44% Public Sector Entities "-  56% Private Sector"

"§  Fragmented Ownership"

-  No Company Owns More Than 3% of Granted Patents "

§  Pharma & Big Bio Are Key Holders "-  Amgen, Novartis, Pfizer &

GSK "

§  Osiris, STEM, & Geron Have Large Estates"

""

*Only 3% of All USPTO Patents Are Held By Public Entities"

Page 44: Marcus evans 2011_commercial_translation_of_regenerative_medicine__funding_strategies_for_rm_companies

Funding & Commercialization Strategies for Regenerative Medicine Companies

Gregory A. BonfiglioProteus Venture Partners"November 15, 2011"